---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-074078"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:30:02.970624+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Entrada reports positive Phase 1 data for ENTR-601-44; plans Phase 2 trials in Q4 2024

## Summary
- No serious or drug-related adverse events; ENTR-601-44 well-tolerated across all 4 dose cohorts (0.75-6 mg/kg) in 32 healthy volunteers.
- At 6 mg/kg, mean exon skipping 0.44% (range 0.3-0.65%), statistically significant vs placebo (p<0.005); muscle concentration mean 53.8 ng/g.
- Plans to submit regulatory applications in Q4 2024 for Phase 2 trials of ENTR-601-44 (exon 44) and ENTR-601-45 (exon 45).
- ENTR-601-50 Phase 2 trial filing expected in 2025; company sees potential for dosing intervals of at least six weeks.

## SEC filing metadata
- accession: 0001104659-24-074078
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465924074078/0001104659-24-074078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465924074078/tm2417848d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-074078
- JSON: https://secwatch.observer/filing/0001104659-24-074078.json
- Plain text: https://secwatch.observer/filing/0001104659-24-074078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.